Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
jump in while you can. the water is fine
Ratings And Price Targets
Cantor analyst Pablo Zuanic maintained the following ratings and price targets on cannabis stocks:
Overweight
Aurora Cannabis Inc. (NYSE: ACB) with a CA$27 price target.
Aphria Inc. (NYSE: APHA) with a CA$9.55 price target.
OrganiGram Holdings Inc (NASDAQ: OGI) with a price target of CA$5.60.
OF course thats the wqy the stars are alighned
OGI PPS is on its way back up. The market has turned in OGI favor.
USA is opening up and OGI has done all the right moves
Good news for the Canadians. up today USA has started to open up.
Tomorrow will be good for OGI. USA will push it up also.
the bottom has been reached and now we go upward
Why Cannabis Stocks Are Surging To Close The Week: The Coronavirus Confusion
2:13 pm ET May 22, 2020 (Benzinga)
Cannabis stocks have been on a steady rise since Thursday morning, with all major U.S. traded ETFs, the ETFMG Alternative Harvest ETF (NYSE: MJ), the AdvisorShares Pure Cannabis ETF (NYSE: YOLO), the Cannabis ETF (NYSE: THCX), and the Amplify Seymour Cannabis ETF (NYSE: CNBS), up by double digits.
Interestingly enough, the main driver of this rally was an item reported by the New York Post on Thursday on information had been out for several days — Benzinga reported on it last week.
Certain strains of cannabis could help block ACE2 gateways, which the coronavirus uses to enter the human body, according to a study conducted by researchers from the University of Lethbridge in Alberta, Canada and published in the Preprints journal — which is not peer-reviewed.
This, the scientists suggested, could reduce the chances of contracting COVID-19 by as much as 80%.
Don’t miss this opportunity to connect with THE cannabis movers and shakers from across the globe during Benzinga’s first Virtual Cannabis Capital Conference on June 1.
Going Viral
As mentioned above, the news about the Canadian study had been out for days.
So, why did stocks react on Thursday?
The answer relates to virality. Not in terms of health, but rather in terms of the internet: the NY Post article went viral, boosting many cannabis stocks.
But, there’s yet another caveat here: it seems CBD is the key ingredient allegedly helping combat coronavirus, the researchers suggested.
Since the NY Post talked about the general term "cannabis," stocks reacted to a potential lift in sales across the board.
In an industry note, Piper Sandler analysts said that "while the merit of the science is difficult to handicap, we believe this type of press could drive a surge in sales for consumers who may not yet have considered CBD as a health and wellness supplement.”
Despite the spike, Piper Sandler decided to keep its ratings, price targets and models for cannabis stocks in their coverage universe unchanged.
Earlier this month, Piper upgraded Aurora Cannabis Inc (NYSE: ACB) following strong quarterly results.
Lead image by Ilona Szentivanyi. Copyright: Benzinga.
$OGI----Monday its going to explode===up and away
OGI HIGH VOLUME TODAY. something is brewing. Could we see an announcement
today???? I could be wrong.
OGI IS NOT TAGGING ALONG FOR RIDE. MAYBE OGI IS GETTING CREATIVE
BUT STILL A SECRET.
Raymond James analysts said Aurora Cannabis Inc.'s (ACB.T) strong stock gains following its recent earnings look overdone compared with the subdued response to stronger numbers from Organigram Inc. (OGI.T) and Village Farms International Inc. . In a note looking at the three companies and their businesses, analysts Rahul Sarugaser and Michael Freeman said the market rewarded Aurora's better-than-expected revenue and overlooked its negative EBITDA. "You gotta be kidding me," the analysts wrote in a note to clients. Aurora's shares have gained 77% in the month to date. "As one of our observant colleagues pointed out: ACB's stock gained in value equivalent to twice that of OGI's entire market cap {about $250 million)-- or thrice that of Village Farms' market cap (@178 million)--after reporting a net loss equivalent to about 50% of OGI's market cap, or 75% of VFF's. Let that sink in," the analysts wrote. Organigram and Village Farms are well operated companies that consistently report positive EBITDA and are capturing market share, said the note. Aurora shares were down 4.5% premarket and are down 43% in the year to date, while the Cannabis ETF (THCX) has fallen 24% and the S&P 500 has fallen 10%.
I know they have the technology but needs to be converted
into revenue making device that can produce volume $$$$$$$$$
HOW to increases revenue at OGI??? POWDERED DRINKS is not the way.
I hope OGI is working to add a distiller to their mix. that would be
the catalyst to start the ball rolling. I pray they are thinking
out of the box.
pre market is again up to start day. NAS DAQ volume yesterday
was 8.63 M . USA IS OPENING all states but business will never
be the same. a lot of damage has uprooted USA and will never be same
economy as prior virus hit. so we move forward. if OGI can find way
to increase revenue it will be a plus.
a trading day for CANADA and stock is down. Go Figure.
what does it take to boost OGI????
yesterday volume was 9.6 M ON NAZ DAQ, PRE MARKET THIS morning
up 4.9% half way thru session. Are we going to see a repeat
oy yesterday???? no news but USA is starting to open up
and placing fear of virus aside.
so far a repeat 0f yesterday could be at the starting gate.
pre market up again this morning. those waiting for a pull back
may be too late. maybe it will but I am not counting on it.
enjoy the ride if it CONTINUES upward.
I think the worst is over any good news will only give OGI a boost
pre market up again this morning. those waiting for a pull back
may be too late. maybe it will but I am not counting on it.
enjoy the ride if it CONTINUES upward.
I think the worst is over any good news will only give OGI a boost
OrganiGram Holdings Inc Is Maintained at Outperform by Raymond James
12:50 pm ET May 15, 2020 (Dow Jones)
OrganiGram Holdings Inc Is Maintained at Outperform by Raymond James
12:50 pm ET May 15, 2020 (Dow Jones)
Organigram Outlines First Phase Of Return-To-Work Strategy
6:05 am ET May 14, 2020 (Benzinga)
As it continues to monitor and assess the implications of the COVID-19 pandemic, Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, has announced the first phase of its return-to-work strategy. The Company has begun to implement a staggered return-to-work plan effective May 13, 2020.
While the Province of New Brunswick currently remains in a state of emergency, the Company has been in contact with government officials to stay abreast of the province’s and provincial health authority’s guidance related to safety and security. Indications suggest conditions in New Brunswick continue to improve and the province may begin to lift some of the current restrictions.
Similarly, Organigram has maintained an open dialogue with jurisdictional and regional partners across the country through the pandemic in order to assess and appropriately respond to consumer demand.
“Throughout the pandemic, two critical factors have driven our decision-making: the health of our employees and the long-term wellness of our business,” says Greg Engel, CEO, Organigram.
“We are pleased to see early signals that conditions are improving across the province as the provincial government has shown strong leadership with their pandemic response. Recognizing that there is still a long road ahead for Canadians and Canadian businesses, we are optimistic as we initiate this first phase of our return-to-work strategy. We also remain committed to thoughtful and informed decisions as we continue to move our business forward.”
The first phase of Organigram’s return-to-work strategy involves recalling approximately 50 employees at the Moncton campus. These employees will fill core roles across various departments that have been deemed highest priority by the Organigram leadership team in this initial phase. Subsequent phases of this plan will be dependent upon public health and safety guidelines and the evolving needs of Organigram’s business.
The safety of employees remains Organigram’s top priority. Safety measures including an increased focus on sanitation and social distancing, with additional hand sanitizing stations throughout the facility, cleaning and sanitizing of high touch surfaces, and additional cleaning in common areas implemented at the outset of the pandemic remain in place at the Organigram facility.
The Company’s leadership team will continue to monitor measures and requirements as mandated by the Province of New Brunswick to ensure a safe and healthy workplace for all employees.Organigram Outlines First Phase Of Return-To-Work Strategy
6:05 am ET May 14, 2020 (Benzinga) Print
As it continues to monitor and assess the implications of the COVID-19 pandemic, Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, has announced the first phase of its return-to-work strategy. The Company has begun to implement a staggered return-to-work plan effective May 13, 2020.
While the Province of New Brunswick currently remains in a state of emergency, the Company has been in contact with government officials to stay abreast of the province’s and provincial health authority’s guidance related to safety and security. Indications suggest conditions in New Brunswick continue to improve and the province may begin to lift some of the current restrictions.
Similarly, Organigram has maintained an open dialogue with jurisdictional and regional partners across the country through the pandemic in order to assess and appropriately respond to consumer demand.
“Throughout the pandemic, two critical factors have driven our decision-making: the health of our employees and the long-term wellness of our business,” says Greg Engel, CEO, Organigram.
“We are pleased to see early signals that conditions are improving across the province as the provincial government has shown strong leadership with their pandemic response. Recognizing that there is still a long road ahead for Canadians and Canadian businesses, we are optimistic as we initiate this first phase of our return-to-work strategy. We also remain committed to thoughtful and informed decisions as we continue to move our business forward.”
The first phase of Organigram’s return-to-work strategy involves recalling approximately 50 employees at the Moncton campus. These employees will fill core roles across various departments that have been deemed highest priority by the Organigram leadership team in this initial phase. Subsequent phases of this plan will be dependent upon public health and safety guidelines and the evolving needs of Organigram’s business.
The safety of employees remains Organigram’s top priority. Safety measures including an increased focus on sanitation and social distancing, with additional hand sanitizing stations throughout the facility, cleaning and sanitizing of high touch surfaces, and additional cleaning in common areas implemented at the outset of the pandemic remain in place at the Organigram facility.
The Company’s leadership team will continue to monitor measures and requirements as mandated by the Province of New Brunswick to ensure a safe and healthy workplace for all employees.Organigram Outlines First Phase Of Return-To-Work Strategy
6:05 am ET May 14, 2020 (Benzinga)
Organigram Outlines First Phase Of Return-To-Work Strategy
6:05 am ET May 14, 2020 (Benzinga)
As it continues to monitor and assess the implications of the COVID-19 pandemic, Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, has announced the first phase of its return-to-work strategy. The Company has begun to implement a staggered return-to-work plan effective May 13, 2020.
While the Province of New Brunswick currently remains in a state of emergency, the Company has been in contact with government officials to stay abreast of the province’s and provincial health authority’s guidance related to safety and security. Indications suggest conditions in New Brunswick continue to improve and the province may begin to lift some of the current restrictions.
Similarly, Organigram has maintained an open dialogue with jurisdictional and regional partners across the country through the pandemic in order to assess and appropriately respond to consumer demand.
“Throughout the pandemic, two critical factors have driven our decision-making: the health of our employees and the long-term wellness of our business,” says Greg Engel, CEO, Organigram.
“We are pleased to see early signals that conditions are improving across the province as the provincial government has shown strong leadership with their pandemic response. Recognizing that there is still a long road ahead for Canadians and Canadian businesses, we are optimistic as we initiate this first phase of our return-to-work strategy. We also remain committed to thoughtful and informed decisions as we continue to move our business forward.”
The first phase of Organigram’s return-to-work strategy involves recalling approximately 50 employees at the Moncton campus. These employees will fill core roles across various departments that have been deemed highest priority by the Organigram leadership team in this initial phase. Subsequent phases of this plan will be dependent upon public health and safety guidelines and the evolving needs of Organigram’s business.
The safety of employees remains Organigram’s top priority. Safety measures including an increased focus on sanitation and social distancing, with additional hand sanitizing stations throughout the facility, cleaning and sanitizing of high touch surfaces, and additional cleaning in common areas implemented at the outset of the pandemic remain in place at the Organigram facility.
The Company’s leadership team will continue to monitor measures and requirements as mandated by the Province of New Brunswick to ensure a safe and healthy workplace for all employees.Organigram Outlines First Phase Of Return-To-Work Strategy
6:05 am ET May 14, 2020 (Benzinga) Print
As it continues to monitor and assess the implications of the COVID-19 pandemic, Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, has announced the first phase of its return-to-work strategy. The Company has begun to implement a staggered return-to-work plan effective May 13, 2020.
While the Province of New Brunswick currently remains in a state of emergency, the Company has been in contact with government officials to stay abreast of the province’s and provincial health authority’s guidance related to safety and security. Indications suggest conditions in New Brunswick continue to improve and the province may begin to lift some of the current restrictions.
Similarly, Organigram has maintained an open dialogue with jurisdictional and regional partners across the country through the pandemic in order to assess and appropriately respond to consumer demand.
“Throughout the pandemic, two critical factors have driven our decision-making: the health of our employees and the long-term wellness of our business,” says Greg Engel, CEO, Organigram.
“We are pleased to see early signals that conditions are improving across the province as the provincial government has shown strong leadership with their pandemic response. Recognizing that there is still a long road ahead for Canadians and Canadian businesses, we are optimistic as we initiate this first phase of our return-to-work strategy. We also remain committed to thoughtful and informed decisions as we continue to move our business forward.”
The first phase of Organigram’s return-to-work strategy involves recalling approximately 50 employees at the Moncton campus. These employees will fill core roles across various departments that have been deemed highest priority by the Organigram leadership team in this initial phase. Subsequent phases of this plan will be dependent upon public health and safety guidelines and the evolving needs of Organigram’s business.
The safety of employees remains Organigram’s top priority. Safety measures including an increased focus on sanitation and social distancing, with additional hand sanitizing stations throughout the facility, cleaning and sanitizing of high touch surfaces, and additional cleaning in common areas implemented at the outset of the pandemic remain in place at the Organigram facility.
The Company’s leadership team will continue to monitor measures and requirements as mandated by the Province of New Brunswick to ensure a safe and healthy workplace for all employees.Organigram Outlines First Phase Of Return-To-Work Strategy
6:05 am ET May 14, 2020 (Benzinga)
Organigram To Recall About 50 Employees At Moncton, New Brunswick Campus In Phase 1 Of Reopening -- MarketWatch
6:18 am ET May 14, 2020 (MarketWatch)
Organigram Holdings Inc. (OGI.T) said Thursday it is recalling abut 50 employees at its Moncton, New Brunswick campus in the first phase of reopening its cannabis business. "These employees will fill core roles across various departments that have been deemed highest priority by the Organigram leadership team in this initial phase," the Canadian company said in a statement. "Subsequent phases of this plan will be dependent upon public health and safety guidelines and the evolving needs of Organigram's business." Safety measures, including enhanced cleaning and hand sanitizing and social-distancing, will be implemented. U.S.-listed shares were not yet active premarket, but have fallen 52% in the year to date, while the ETFMG Alternative Harvest ETF (MJ) has fallen 36% and the S&P 500 has fallen 13%.
Organigram To Recall About 50 Employees At Moncton, New Brunswick Campus In Phase 1 Of Reopening -- MarketWatch
6:18 am ET May 14, 2020 (MarketWatch)
Organigram Holdings Inc. (OGI.T) said Thursday it is recalling abut 50 employees at its Moncton, New Brunswick campus in the first phase of reopening its cannabis business. "These employees will fill core roles across various departments that have been deemed highest priority by the Organigram leadership team in this initial phase," the Canadian company said in a statement. "Subsequent phases of this plan will be dependent upon public health and safety guidelines and the evolving needs of Organigram's business." Safety measures, including enhanced cleaning and hand sanitizing and social-distancing, will be implemented. U.S.-listed shares were not yet active premarket, but have fallen 52% in the year to date, while the ETFMG Alternative Harvest ETF (MJ) has fallen 36% and the S&P 500 has fallen 13%.
Get ready for a up day on 5/13. THE AFTER NARKET IS STRONG.LOOKS
LIKE OGI has stopped selling driving the price down. if I am right
watch the pps rise tomorrow.
Get ready for a update on 5/13. THE AFTER NARKET IS STRONG.LOOKS
LIKE OGI has stopped selling driving the price down. if I am right
watch the pps rise tomorrow.
Get ready for a update on 5/13. THE AFTER NARKET IS STRONG.LOOKS
LIKE OGI has stopped selling driving the price down. if I am right
watch the pps rise tomorrow.
Get ready for a update on 5/13. THE AFTER NARKET IS STRONG.LOOKS
LIKE OGI has stopped selling driving the price down. if I am right
watch the pps rise tomorrow.
Get ready for a update on 5/13. THE AFTER NARKET IS STRONG.LOOKS
LIKE OGI has stopped selling driving the price down. if I am right
watch the pps rise tomorrow.
Fervor for CBD Products Spreads Around the Globe
9:00 am ET May 6, 2020 (PR Newswire) Print
Around the globe, countries are legalizing cannabis for both medical and recreational uses. The demand for cannabis has gradually increased over time, and particularly in the recent years as it captured the attention of consumers due to its unique properties, coupled with its medical benefits. Now, the growing therapeutic applications associated with cannabis are expected to create several opportunities for companies operating in the market. The advent of cannabis-infused products such as edibles and drinks is also anticipated to further aid the growth of the marijuana market in the coming years. In fact, the market has come so far that the United States passed the Farm Bill in late 2018. The bill legalized hemp-derived CBD products as long as they contained 0.3% THC or less, making CBD-derived products available across the U.S. However, industry experts believe that the recreational cannabis market will eventually dwarf its medical counterpart due to legalization efforts around the world gaining momentum. And according to data compiled by MarketsandMarkets, the global cannabis market was valued at USD 10.3 Billion in 2018. By 2023, the market is expected to reach USD 39.4 Billion while exhibiting a CAGR of 30.7% during the forecast period. World High Life Plc (OTC: WRHLF), KushCo Holdings, Inc. (OTC: KSHB), Organigram Holdings Inc. (NASDAQ: OGI), 22nd Century Group, Inc. (NYSE: XXII), Planet 13 Holdings Inc. (OTC: PLNHF)
CBD is the active chemical found within the hemp plant, which falls under the cannabis family. According to Healthline, certain CBD products may be effective for physical conditions as well; For example, one study on rats found that CBD oil may treat pain associated with arthritis, while another study on human cells found that CBD cream was an effective anti-inflammatory. "The work to date on marijuana and cannabinoids has given promising but conflicting signals on potential benefit for motor and non-motor symptoms as well as levodopa-induced dyskinesia. This therapy may represent a future treatment option for PD, but the correct dose and formulation are not clear, full side effects and drug interactions are unknown, and benefits have not been rigorously determined. Future studies should be large and well designed to provide clear data on the safety and efficacy of marijuana and cannabinoids in Parkinson's," said Rachel Dolhun, MD, Vice President, Medical Communications at The Michael J. Fox Foundation for Parkinson's Research.
World High Life Plc (OTCQB: WRHLF), the AQSE and OTCQB listed investment company announced breaking news today, "on the progress of its wholly owned subsidiary, Love Hemp, during the global covid-19 pandemic.
Love Hemp is passionate about creating the UK's leading range of trusted CBD products, with new product development at the heart of the brand. Love Hemp was the first functional spring water in the UK to be infused with CBD. Oils, sprays, vapes, chocolate, jelly domes and beauty products including the first CBD infused face mask and body salves have all followed. In response to current challenges, the brand has shifted its focus, building on the opportunity to achieve stronger online sales, achieving a 39% increase month-on-month since January 2020, whilst expanding its offerings to meet consumer demand.
Highlights Corporate Highlights
-- The Love Hemp brand (www.love-hemp.com) has increased online sales by 39% month over month since January 2020
-- The brand has secured a number of notable listings with leading retailers including Boots, Ocado, Holland and Barrett and Sainsbury's
-- The brand is now the best-selling CBD brand for Alliance Healthcare, the UK's leading distributor to Pharmacies and Independent Retailers, based on sales channel feedback
-- The brand is in negotiations with some of the UKs' largest retailers for multiple SKU new listings from September 2020
-- To support growing demand and sales CBDOilsUK (www.cbdoilsuk.com) is expanding its product portfolio with three new brands and a renewed web presence in the near future
-- LH Botanicals (www.lhbotanicals.com), the Company's CBD wholesale production business, is adding production capacity and new product lines with the acquisition of new machines
Having secured a number of notable listings with leading retailers including Boots, Ocado, Holland and Barrett and Sainsbury's, as well as being recognized on the list of Best CBD Oil Brands in the UK by the Evening Standard in August 2019, the brand also won The Beauty Shortlist Award 2020.
New product development is at the heart of the business, with Love Hemp Immune launching in April 2020, more than six-months ahead of schedule, highlighting the brands ability to be flexible and agile, whilst responding to consumer needs amidst the current circumstances. There is also a range of new products in development ranging from confectionary to drinks, oils and sprays. Re-branding work carried out by external marketing partners, Propaganda, will be live in retail stores and online from October 2020.
Additionally, the company's global online retailer, CBDOilsUK is expanding its product portfolio with the launch of three brands within the next two months, whilst its wholesale production unit LH Botanicals is committed to fully supporting customers through this challenging time and as such has increased production capacity with the acquisition of new capsule and bath bomb production machines.
Tony Calamita, CEO at Love Hemp commented: 'There's no question that the challenges businesses across the world are facing currently is unique. Whilst bricks and mortar stores have either closed or experienced less foot traffic and reduced hours, it has highlighted the need for us to have a robust online presence in order to keep people engaged with our brands and products. We have expanded our online offerings, and are committed to continuing to provide the best experience for our customers, so they are able to continue to purchase and engage with us in an efficient way, with minimal disruption. Fortunately, consumer demand for our products is growing and we have adapted thanks to a great team effort to be able to grow the business under new circumstances, ones like the expansion of our e-commerce presence and education marketing that will be the foundations of our model going forward.'"
KushCo Holdings, Inc. (OTCQX: KSHB) announced earlier this year that the partnership with Xtraction Services Holding Corp., a rapidly growing specialty finance company that provides equipment leasing solutions to owners and operators of cannabis and hemp companies in the United States, to offer equipment financing to KushCo's network of thousands of compliant cannabis and CBD operators. "For the past several months, we have been evaluating ways in which we can successfully enter the equipment financing arena, which we identified early on as being another growth driver and margin accretive business that can significantly complement our existing ecosystem of ancillary products and services," said Nick Kovacevich, KushCo's Co-founder, Chief Executive Officer, and Chairman.
Organigram Holdings Inc. (NASDAQ: OGI) announced on January 16th, 2020 that it had secured a supply agreement with Medical Cannabis by Shoppers, the online medical cannabis platform by Shoppers Drug Mart Inc. "We are extremely proud to partner with Shoppers and believe that our complementary approach to the medical cannabis market will offer the full strength of our combined national networks to Canadian patients," says Tim Emberg, Senior Vice President of Sales and Commercial Operations. "We are pleased that we will now be able to offer medical cannabis patients across the country even greater access to our growing portfolio of high-qutality products." to News Results
Fervor for CBD Products Spreads Around the Globe
9:00 am ET May 6, 2020 (PR Newswire) Print
Around the globe, countries are legalizing cannabis for both medical and recreational uses. The demand for cannabis has gradually increased over time, and particularly in the recent years as it captured the attention of consumers due to its unique properties, coupled with its medical benefits. Now, the growing therapeutic applications associated with cannabis are expected to create several opportunities for companies operating in the market. The advent of cannabis-infused products such as edibles and drinks is also anticipated to further aid the growth of the marijuana market in the coming years. In fact, the market has come so far that the United States passed the Farm Bill in late 2018. The bill legalized hemp-derived CBD products as long as they contained 0.3% THC or less, making CBD-derived products available across the U.S. However, industry experts believe that the recreational cannabis market will eventually dwarf its medical counterpart due to legalization efforts around the world gaining momentum. And according to data compiled by MarketsandMarkets, the global cannabis market was valued at USD 10.3 Billion in 2018. By 2023, the market is expected to reach USD 39.4 Billion while exhibiting a CAGR of 30.7% during the forecast period. World High Life Plc (OTC: WRHLF), KushCo Holdings, Inc. (OTC: KSHB), Organigram Holdings Inc. (NASDAQ: OGI), 22nd Century Group, Inc. (NYSE: XXII), Planet 13 Holdings Inc. (OTC: PLNHF)
CBD is the active chemical found within the hemp plant, which falls under the cannabis family. According to Healthline, certain CBD products may be effective for physical conditions as well; For example, one study on rats found that CBD oil may treat pain associated with arthritis, while another study on human cells found that CBD cream was an effective anti-inflammatory. "The work to date on marijuana and cannabinoids has given promising but conflicting signals on potential benefit for motor and non-motor symptoms as well as levodopa-induced dyskinesia. This therapy may represent a future treatment option for PD, but the correct dose and formulation are not clear, full side effects and drug interactions are unknown, and benefits have not been rigorously determined. Future studies should be large and well designed to provide clear data on the safety and efficacy of marijuana and cannabinoids in Parkinson's," said Rachel Dolhun, MD, Vice President, Medical Communications at The Michael J. Fox Foundation for Parkinson's Research.
World High Life Plc (OTCQB: WRHLF), the AQSE and OTCQB listed investment company announced breaking news today, "on the progress of its wholly owned subsidiary, Love Hemp, during the global covid-19 pandemic.
Love Hemp is passionate about creating the UK's leading range of trusted CBD products, with new product development at the heart of the brand. Love Hemp was the first functional spring water in the UK to be infused with CBD. Oils, sprays, vapes, chocolate, jelly domes and beauty products including the first CBD infused face mask and body salves have all followed. In response to current challenges, the brand has shifted its focus, building on the opportunity to achieve stronger online sales, achieving a 39% increase month-on-month since January 2020, whilst expanding its offerings to meet consumer demand.
Highlights Corporate Highlights
-- The Love Hemp brand (www.love-hemp.com) has increased online sales by 39% month over month since January 2020
-- The brand has secured a number of notable listings with leading retailers including Boots, Ocado, Holland and Barrett and Sainsbury's
-- The brand is now the best-selling CBD brand for Alliance Healthcare, the UK's leading distributor to Pharmacies and Independent Retailers, based on sales channel feedback
-- The brand is in negotiations with some of the UKs' largest retailers for multiple SKU new listings from September 2020
-- To support growing demand and sales CBDOilsUK (www.cbdoilsuk.com) is expanding its product portfolio with three new brands and a renewed web presence in the near future
-- LH Botanicals (www.lhbotanicals.com), the Company's CBD wholesale production business, is adding production capacity and new product lines with the acquisition of new machines
Having secured a number of notable listings with leading retailers including Boots, Ocado, Holland and Barrett and Sainsbury's, as well as being recognized on the list of Best CBD Oil Brands in the UK by the Evening Standard in August 2019, the brand also won The Beauty Shortlist Award 2020.
New product development is at the heart of the business, with Love Hemp Immune launching in April 2020, more than six-months ahead of schedule, highlighting the brands ability to be flexible and agile, whilst responding to consumer needs amidst the current circumstances. There is also a range of new products in development ranging from confectionary to drinks, oils and sprays. Re-branding work carried out by external marketing partners, Propaganda, will be live in retail stores and online from October 2020.
Additionally, the company's global online retailer, CBDOilsUK is expanding its product portfolio with the launch of three brands within the next two months, whilst its wholesale production unit LH Botanicals is committed to fully supporting customers through this challenging time and as such has increased production capacity with the acquisition of new capsule and bath bomb production machines.
Tony Calamita, CEO at Love Hemp commented: 'There's no question that the challenges businesses across the world are facing currently is unique. Whilst bricks and mortar stores have either closed or experienced less foot traffic and reduced hours, it has highlighted the need for us to have a robust online presence in order to keep people engaged with our brands and products. We have expanded our online offerings, and are committed to continuing to provide the best experience for our customers, so they are able to continue to purchase and engage with us in an efficient way, with minimal disruption. Fortunately, consumer demand for our products is growing and we have adapted thanks to a great team effort to be able to grow the business under new circumstances, ones like the expansion of our e-commerce presence and education marketing that will be the foundations of our model going forward.'"
KushCo Holdings, Inc. (OTCQX: KSHB) announced earlier this year that the partnership with Xtraction Services Holding Corp., a rapidly growing specialty finance company that provides equipment leasing solutions to owners and operators of cannabis and hemp companies in the United States, to offer equipment financing to KushCo's network of thousands of compliant cannabis and CBD operators. "For the past several months, we have been evaluating ways in which we can successfully enter the equipment financing arena, which we identified early on as being another growth driver and margin accretive business that can significantly complement our existing ecosystem of ancillary products and services," said Nick Kovacevich, KushCo's Co-founder, Chief Executive Officer, and Chairman.
Organigram Holdings Inc. (NASDAQ: OGI) announced on January 16th, 2020 that it had secured a supply agreement with Medical Cannabis by Shoppers, the online medical cannabis platform by Shoppers Drug Mart Inc. "We are extremely proud to partner with Shoppers and believe that our complementary approach to the medical cannabis market will offer the full strength of our combined national networks to Canadian patients," says Tim Emberg, Senior Vice President of Sales and Commercial Operations. "We are pleased that we will now be able to offer medical cannabis patients across the country even greater access to our growing portfolio of high-qutality products."
Thanks GMASON I can always count on you for a honest answer.
DO YOU KNOW WHAT THE CANDY REVENUE WAS??? MUST HAVE BEEN A VERY LOW NUMBER.
A CANDY FACTORY????? Maybe they can convert it into a medical factory.
IS THE CANDY FACTORY A QUESTIONABLE DREAM???????
Organigram Reports Second Quarter Fiscal 2020 Results
BusinessWire
Canadian cannabis company OrganiGram loss widens in latest quarter as revenue falls short of estimates
MarketWatch
OrganiGram Holdings Inc. Is Maintained at Outperform by Raymond James
Dow Jones
OrganiGram May Underperform Broader Cannabis Market In Q2, Says Cantor Fitzgerald
1:41 pm ET April 1,
OrganiGram Holdings Inc (NASDAQ: OGI) is scheduled to report second-quarter results before the market opens on April 14.
Although the quarterly results are unlikely to be a near-term catalyst for the stock, the company is among the better-managed licensed producers of cannabis and is profitable, according to Cantor Fitzgerald.
The OrganiGram Analyst
Pablo Zuanic maintained an Overweight on OrganiGram Holdings and reduced the price target from CA$9 ($6.32) to CA$5.80 ($4.07).
The OrganiGram Thesis
The overall recreational cannabis market is likely to have generated more than 8% sequential sales growth in February, implying total market growth of 21% for the February quarter, Zuanic said in a Wednesday note. (See his track record here.)
Yet OrganiGram is unlikely to post this kind of sequential growth in the second quarter in light of the company’s sales growth in recreational cannabis in the prior quarter, the analyst said.
In the November quarter, OrganiGram’s sales of recreational cannabis declined by 4% and the company’s overall sales growth was driven by the wholesale business, which generated $9.2 million in sales, he said.
Zuanic said he expects OrganiGram’s margins to be under pressure due to a higher marketing spend and start-up costs related to its new product lines.
The company is approaching positive operating cash flow and its stock valuation is attractive, according to Cantor Fitzgerald. to News Results
OrganiGram May Underperform Broader Cannabis Market In Q2, Says Cantor F
PRE MARKET IS UP THIS MORNING 3/27
OrganiGram Holdings Inc. Is Maintained at Outperform by Raymond James
11:56 am ET March 24, 2020
Organigram Receives Health Canada License Renewal and Expansion for Final Elements of Phase 5 and Provides COVID-19 Update
9:23 am ET March 23, 2020 (BusinessWire)
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that the Company has received Health Canada's approval for the licensing of the remainder of its Phase 5 expansion together with the renewal of its licenses for standard cultivation, standard processing and sale for medical purposes under the Cannabis Regulations. The renewed and expanded licenses are effective as of March 20, 2020.
Licensing
The terms of the licenses include approval of a two-floor production facility designed to support all processing activity as well as dedicated spaces for packaging of flower, pre-rolls, vape pens and powdered beverages.
The Phase 5 expansion also includes a new extraction facility with increased capacity for CO2 extraction, and winterization as well as new capabilities designed for future product development.
The amendments also allow for new purpose-built harvest and drying rooms and support areas for quality assurance, maintenance and sanitation.
The licenses are valid for a three-year period until March 20, 2023 and are subject to customary terms and conditions.
COVID-19
The Company has been carefully monitoring and actively planning for the evolving situation related to COVID-19 and potential impacts on the Company's business and operations. The Company is managing its production and staffing levels at its Moncton facility (where not all functions can be addressed remotely) to protect the health of its employees and the community. The Company currently expects that its workforce will be materially reduced as a result of voluntary and company-imposed temporary lay-offs to facilitate adequate social distancing while the COVID-19 situation lasts. This will result in corresponding production and packaging reductions. The situation is evolving and it is not yet possible to quantify these anticipated changes. The Company plans, among other things, to reallocate its remaining workforce as needed, utilize inventory already on hand and focus on leveraging its most efficient and automated lines of production.
"We continue to monitor this rapidly changing situation and will make the decisions necessary to ensure the safest environment for our employees and their families as well as protecting the best interests of our business and our stakeholders," said Greg Engel, Chief Executive Officer.
PRE MARKET IS UP. B/A is siding with OGI. Organigram Should Meet Estimates
Carey upgraded Organigram Holdings (NASDAQ: OGI) from Underperform to Neutral with a $1.72 price objective.
“In OGI, we see a company with focus capable of delivering consistent sales/profit,” the analyst said, adding that he believes that the rise in demand could mean a tailwind for Organigram as well.
With good positioning in the derivative products category, free cash flow in sight and sufficient liquidity, BofA expects the company to reach its fiscal year estimates, he said.
CORONAVIRUS WILL BE CONQUERED
Hemp's Resurgence Continues as the FDA Hones in on CBD
9:00 am ET March 19, 2020 (PR Newswire) Print
CBD has garnered a strong reputation for its wide range of potential health benefits. However, it has only been approved to treat childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome after the U.S. Food and Drug Administration approved Epidiolex, making it the first approved cannabis-based drug, last year. The FDA has made clear that additional research is required in order to advance with more approvals. The Administration has also held numerous public hearings in recent years in order to further understand the efficacy of CBD. And while only one cannabis-based drug has been approved, the efforts of the FDA indicate that CBD is gathering a strong momentum as a possible medical substance. "As legislation expands rapidly worldwide, the volume of efficacy data is growing, as are legitimate clinical trial studies," says Liam McGreevy, Chief Executive Officer of Ethnopharm, a European cannabis company specializing in genetics and distribution, "This data will enable us to better understand the effects of the various cannabinoids and terpenes, their synergistic effect and how their impact links to the individual's genetics or biomarkers. This data is key to understanding the most effective combinations and strengths for various conditions, moving towards targeted personalized medicines." And according to data compiled by Acumen Research and Consulting, the global cannabidiol (CBD) market is projected to reach USD 22 Billion by 2026 while exhibiting a CAGR of 33% over the forecast period, from 2019 to 2026. Cardiol Therapeutics Inc. (OTC: CRTPF) (TSX: CRDL), Tilray, Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON), Innovative Industrial Properties, Inc. (NYSE: IIP), Organigram Holdings Inc. (NASDAQ: OGI)